Expression of CD166 in non-small cell lung cancer tissues and its relationship with platinum-based chemotherapy effect
10.3760/cma.j.issn.1008-6706.2014.01.008
- VernacularTitle:活化白细胞黏附分子在非小细胞肺癌组织中的表达及其与铂类化疗效果的相关性研究
- Author:
Xiaoming YE
;
Zhengwen CHENG
;
Pingman YANG
;
Hongyang WANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Activated-leukocyte cell adhesion molecule;
Immunohistochemistry;
Cisplatin;
Carboplatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;21(1):16-18
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the expression of CD166 in advanced non-small cell lung cancer (NSCLC),and to explore the relationship between expression of CD166 and clinical characteristics,platinum-based chemotherapy effect of NSCLC patients.Methods A total of 64 cases of NSCLC patients at stage of Ⅲ,Ⅳ were enrolled.Tumor tissue samples were obtained before chemotherapy by bronchoscopy or lung biopsy,and immunohistochemical was used to detect the expression of CD166.All patients received platinum-based chemotherapy(NP/TC/ GP) for 2-4 cycles as the first line treatment.RECIST criterion was used for therapeutic evaluation.Results 46.9% (3 0 cases) of the patients with CD 1 6 6 was positive.The CD 1 6 6 expression was related with smoking (smoking 62.1%,no-smoking 34.3%,x2 =4.916,P =0.027) and degree of differentiation (moderately,low grade 68.2%,high grade 35.7%,x2 =6.112,P =0.013).The effectiveness rate of chemotherapy in CD166 positive patients was 23.3% (7 cases),was significantly lower than 61.8% in CD166 negative patients(21 cases,x2 =9.565,P =0.002).Conclusion NSCLC had CD166 expression,and the expression positive rate was increased in patients with smoking,and low differentiation cancer.The effectiveness rate of platinum-based was decreased in patients with CD166 positive expression,and detection of CD166 can predict the late NSCLC platinum-based chemotherapy effect.
